HealthTechFundingNewsabout 1 hour ago
Swiss Biotech Secures $135M for Vaccine
5 min read
Swiss biotech Nouscom raised $135 million in a Series D round co-led by M Ventures and Revelation Partners. The funding supports a global trial of the NOUS-209 vaccine for Lynch syndrome carriers. The US FDA granted Fast Track designation on June 1, 2026. Early data show 85% of participants maintained immune responses after one year.
Level
Hype check
Tap to vote and see what everyone thinks.
